Enanta Pharmaceuticals, Inc. Announced the appointment of Scott T. Rottinghaus, M.D., to the position of Senior Vice President and Chief Medical Officer, effective August 8, 2022. Dr. Rottinghaus joins Enanta from Alexion, AstraZeneca Rare Disease, where he was Vice President and Head of Clinical Development for Hematology and Nephrology. Dr. Rottinghaus is an infectious disease trained physician who has more than 20 years of experience in drug development across a broad range of therapeutic areas.

He will lead the development, regulatory, clinical and medical functions in support of Enanta's pipeline.